Matthew I. Milowsky, M.D.
Section Chief of Genitourinary Oncology
UNC Lineberger Comprehensive Cancer Center

Matthew I. Milowsky, M.D. is the Section Chief of Genitourinary Oncology at the UNC Lineberger Comprehensive Cancer Center. Previously, Dr. Milowsky was an assistant member of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center and an Assistant Professor of Medicine at Weill Medical College of Cornell University.  Dr. Milowsky completed a fellowship in Medical Oncology and Hematology at the New York Presbyterian Hospital-Weill Medical College of Cornell University.  After completing his fellowship training, he remained on staff at New York Presbyterian Hospital-Cornell and focused on the treatment of patients with and research related to genitourinary malignancies.  He subsequently joined the Genitourinary Oncology Service at Memorial-Sloan Kettering Cancer Center and has continued to pursue research related to urologic cancers with a focus on the development of novel therapies for patients with advanced bladder and other urothelial cancers. 

Dr. Milowsky has published in peer reviewed journals and written several chapters including serving as a co-author on the Genitourinary Cancers section of the ASCO Medical Oncology Self-Evaluation Program.  He has also served as faculty at many meetings including the ASCO-ABIM sponsored Medical Oncology Knowledge Workshop.  Dr. Milowsky has received several honors and awards including an NIH Institutional Research Fellowship Award in Hematology, DOD Physician Research Training Award, the Weill Cornell Hematology/Oncology Faculty Teaching Award and the MSKCC Paul Sherlock Housestaff Teaching Award.  He is the principal investigator of an ongoing research project supported by an American Association for Cancer Research (AACR) Henry Shepard Grant for Bladder Cancer Research. This effort, titled the Bladder Cancer Oncogenome Project, aims to identify molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies in patients with urothelial cancer.